Methylphenidate has 20 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Maois), Safinamide Mesylate, Gastric Ph Modulators (H2-Blockers, Proton Pump Inhibitors). Patients taking Methylphenidate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Contraindicated
- 2
- Major
- 2
- Moderate
- 16
Contraindicated (2)
- Methylphenidate + Monoamine Oxidase Inhibitors (Maois)— Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarc…
- Methylphenidate + Safinamide Mesylate— Sympathomimetic medication; concomitant use is contraindicated due to risk of hypertensive crisis.
Major (2)
- Methylphenidate + Gastric Ph Modulators (H2-Blockers, Proton Pump Inhibitors)— May change the release profile and alter the pharmacodynamics of methylphenidate. Concomitant use is not recommended.
- Methylphenidate + Topical Local Anesthetics— Concomitant use may increase risk of sudden blood pressure and heart rate increase during surgery. Avoid use on day of s…
Moderate (16)
- Methylphenidate + Clomipramine— Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma conc…
- Methylphenidate + Clomipramine Hydrochloride— Methylphenidate increases plasma levels of tricyclic antidepressants including clomipramine.
- Methylphenidate + Clomipramine Hydrochloride Capsules— Methylphenidate may increase plasma levels of clomipramine; close supervision and dosage adjustment recommended.
- Methylphenidate + Desipramine— Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma conc…
- Methylphenidate + Esketamine Hydrochloride— Concomitant use may increase blood pressure. Closely monitor blood pressure with concomitant use.
- Methylphenidate + Fosphenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
- Methylphenidate + Imipramine— Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma conc…
- Methylphenidate + Ioflupane I-123— Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.
- Methylphenidate + Midazolam Hydrochloride— Chronic administration may result in inadequate sedation with midazolam due to decreased absorption.
- Methylphenidate + Oral Anticoagulants— Methylphenidate may inhibit metabolism of coumarin anticoagulants. Downward dose adjustments may be required and coagula…
- Methylphenidate + Phenobarbital— Methylphenidate may inhibit metabolism of this anticonvulsant. Downward dose adjustments may be required.
- Methylphenidate + Phenytoin— Methylphenidate may inhibit metabolism of this anticonvulsant. Downward dose adjustments may be required.
- Methylphenidate + Phenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
- Methylphenidate + Primidone— Methylphenidate may inhibit metabolism of this anticonvulsant. Downward dose adjustments may be required.
- Methylphenidate + Risperidone— Concomitant use with methylphenidate may increase the risk of extrapyramidal symptoms (EPS), especially with dosage chan…
- Methylphenidate + Selective Serotonin Reuptake Inhibitors (Ssri)— Methylphenidate may inhibit metabolism of SSRIs. Downward dose adjustments may be required and plasma concentrations sho…